Therapeutic Asset Ratings

470 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Glecirasib Lung Cancer	Sun Yat-sen University	P2	CCC (53)
Glecirasib Mutation	Sun Yat-sen University	P2	CCC (53)
gsk1120212 MET Exon 14 Mutation	Sun Yat-sen University	P2	CCC (53)
gsk1120212 Mutation	Sun Yat-sen University	P2	CCC (53)
Icotinib EGFR L861Q	Sun Yat-sen University	P2	CCC (53)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER CD5 Positive	Sun Yat-sen University	P2	CCC (53)
Inno-206 CD5 Positive	Sun Yat-sen University	P2	CCC (53)
Iparomlimab Beta Blocker	Sun Yat-sen University	P2	CCC (53)
Iparomlimab Iparomlimab and Tuvonralimab	Sun Yat-sen University	P2	CCC (53)
Iparomlimab Neoadjuvant Chemoimmunotherapy	Sun Yat-sen University	P2	CCC (53)
Irinotecan Cytoreductive Surgery	Sun Yat-sen University	P2	CCC (53)
Irinotecan Hyperthermic Intraperitoneal Chemotherapy	Sun Yat-sen University	P2	CCC (53)
Irinotecan Ivonescimab	Sun Yat-sen University	P2	CCC (53)
Irinotecan Radiotherapy, Intensity-Modulated	Sun Yat-sen University	P2	CCC (53)
Ivonescimab Ivonescimab	Sun Yat-sen University	P2	CCC (53)
Jwcar029 Mantle Cell Lymphoma	Sun Yat-sen University	P2	CCC (53)
Larotrectinib Lung Cancer	Sun Yat-sen University	P2	CCC (53)
Larotrectinib Mutation	Sun Yat-sen University	P2	CCC (53)
L-Dep Safety and Efficacy	Sun Yat-sen University	P2	CCC (53)
LENVATINIB CNLC IIIA Stage	Sun Yat-sen University	P2	CCC (53)
LENVATINIB Iparomlimab and Tuvonralimab	Sun Yat-sen University	P2	CCC (53)
LENVATINIB Macrovascular Invasion	Sun Yat-sen University	P2	CCC (53)
Lparomlimab Rectal Cancer	Sun Yat-sen University	P2	CCC (53)
Lubiprostone MSS Metastatic Colorectal Cancer	Sun Yat-sen University	P2	CCC (53)
Lubiprostone Peritoneal Carcinomatosis	Sun Yat-sen University	P2	CCC (53)

Showing 201 to 225 of 470 assets

PreviousPage 9 of 19Next